Clinical trials: Advanced Solid Tumors Patients
Advanced Solid Tumors
Nivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe)
The purpose of this study is to determine the safety and effectiveness of nivolumab alone or in combination with ipilimumab in patients with metastatic or unresectable tumors harbouring mutations in genes, POLE and POLD1.
- Trial name
- NIMBLe (NCT03461952)
- Testing
- Nivolumab, Ipilimumab
- Where
- 6 sites in United States, Canada
- Volunteers
- 4 people
- Sponsor
- Canadian Cancer Trials Group
Metastatic Neoplasm
A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Primary Objectives: Dose Escalation: To determine maximum tolerated dose (MTD) or maximum administered dose (MAD) and overall safety and tolerability profile of SAR441000 when administered intratumorally as monotherapy and in…
- Trial name
- NCT03871348
- Testing
- SAR441000, Cemiplimab REGN2810
- Where
- 19 sites in United States, Belgium and 4 more
- Volunteers
- 77 people
- Sponsor
- Sanofi
FGFR2 Amplification, FGFR2 Gene Mutation
REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors
This is a Phase 1/2, open-label, FIH study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDy), and antineoplastic activity of RLY-4008, a potent and highly selective FGFR2 inhibitor, in…
- Conditions
- FGFR2 Amplification, FGFR2 Gene Mutation, FGFR2 Gene Fusion/Rearrangement, FGFR2 Gene Translocation
- Trial name
- NCT04526106
- Testing
- RLY-4008
- Where
- 48 sites in United States, Australia and 11 more
- Volunteers
- 490 people
- Sponsor
- Elevar Therapeutics
Oncology
Phase I Study to Determine the Maximum Tolerable Dose of BAY94-9343 in Patients With Advanced Solid Tumors.
BAY94-9343 was an antibody-drug conjugate (ADC) directed against the cancer antigen mesothelin on tumor cells.
- Trial name
- NCT01439152
- Testing
- BAY94-9343, BAY94-9343 (Expansion), BAY94-9343 (1.8 mg/kg)
- Where
- 8 sites in United States
- Volunteers
- 148 people
- Sponsor
- Bayer
Patients With Any Advanced Solid Tumors
Trial Of Pembrolizumab And Nintedanib
Both anti-angiogenesis and anti PD1 immunotherapy have shown beneficial efficacy in solid tumors and in particular in NSCLC. Therefore it is of interest to investigate whether the combination of these two approaches is tolerable.
- Trial name
- PEMBIB (NCT02856425)
- Testing
- Nintedanib, Pembrolizumab
- Where
- 5 sites in France
- Volunteers
- 196 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
The purpose of this study is to find out whether the study drug, LY3537982, is safe and effective in cancer patients who have a specific genetic mutation (KRAS G12C).
- Conditions
- Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Endometrial Neoplasms, Ovarian Neoplasms
- Trial name
- NCT04956640
- Testing
- LY3537982, Pembrolizumab, Cetuximab
- Where
- 49 sites in United States, Australia and 4 more
- Volunteers
- 540 people
- Sponsor
- Eli Lilly and Company
Solid Tumor, Breast Cancer
Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour Patients
This Phase Ib/II study is an open label, multicenter study. The study is divided in two parts: Phase I: an open-label, dose escalation study of F16IL2 in combination with paclitaxel for patients with solid tumours, bladder…
- Conditions
- Solid Tumor, Breast Cancer, Metastatic Melanoma, Non-small Cell Lung Cancer (NSCLC)
- Trial name
- NCT01134250
- Testing
- F16IL2 in combination with paclitaxel
- Where
- 5 sites in Italy
- Volunteers
- 48 people
- Sponsor
- Philogen S.p.A.
Advanced Malignancies
A Clinical Trial of TQB6426 for Injection in Patients With Advanced Solid Tumors
TQB6426 is a glypican-3 (GPC3)-targeted antibody-drug conjugate (ADC) independently developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Trial name
- NCT07730190
- Testing
- TQB6426 for Injection
- Where
- 8 sites in China
- Volunteers
- 145 people
- Sponsor
- Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Advanced Solid Tumors, Metastatic Solid Tumors
Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Combination With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Solid Tumors
A Phase I dose escalation study to determine the safety, tolerability, pharmacodynamics and preliminary anti-tumor activity of BMS-754807 in combination with chemotherapy drugs, paclitaxel and carboplatin, in patients with…
- Trial name
- NCT00793897
- Testing
- BMS-754807, Paclitaxel, Carboplatin
- Where
- 5 sites in Australia, Canada and 1 more
- Volunteers
- 21 people
- Sponsor
- Bristol-Myers Squibb
Advanced Cancer
A Study of BMS-986205 Alone and in Combination With Nivolumab in Chinese Patients With Advanced Malignant Solid Tumors
The purpose of this study is to determine safety and effectiveness of experimental medication BMS-986205 in combination with Nivolumab in patients with cancers that are advanced or have spread.
- Trial name
- NCT03792750
- Testing
- BMS-986205, Nivolumab
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Bristol-Myers Squibb
Advanced Cancer
AST-021p Study in Advanced Solid Tumors
The purpose of this study is to evaluate the safety, tolerability and optimal Immunogenic dose of therapeutic cancer vaccine (AST-021p) in patients With advanced solid tumors A phase 1 study
- Trial name
- NCT04864418
- Testing
- AST-021p
- Where
- 3 sites in South Korea
- Volunteers
- 22 people
- Sponsor
- Aston Sci. Inc.
Advanced Cancer, Metastatic Cancer
Personalized Vaccine Generated by Autologous Dendritic Cells Pulsed With Autologous Whole Tumor Cell Lysate Treat Advanced Solid Tumor Patients With High Tumor Mutation Burden
The study is to investigate the safety and efficacy of dendritic cells vaccines pulsed with autologous whole tumor cell lysate for treating advanced solid tumor patients with high tumor mutation burden.
- Trial name
- NCT03671720
- Testing
- personalized DC vaccine
- Where
- China
- Sponsor
- Capital Medical University
Advanced Malignant Solid Neoplasm, Locally Advanced Malignant Solid Neoplasm
Integrative Palliative Care/Psycho-Oncology Telehealth Intervention in Patients With Advanced Cancer
This trial investigates whether a joint and integrative approach to cancer care using palliative care and psycho-oncology is possible, and if it's beneficial to patients with cancer that has spread to other places on the body…
- Conditions
- Advanced Malignant Solid Neoplasm, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
- Trial name
- NCT04697524
- Testing
- Support Group Therapy, Symptom Management Service (SMS) Consultation, Quality of Life (QOL) Questionnaires
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of California, San Francisco
Advanced Solid Tumors
Evaluation of the Safety and Efficacy of NBL-015 in Patients With Advanced Solid Tumors
This trial is an open-label, multicenter, dose-escalation and cohort-expansion Phase I clinical study in patients with advanced solid tumors.
- Trial name
- NCT05153096
- Testing
- NBL-015
- Where
- China
- Volunteers
- 410 people
- Sponsor
- NovaRock Biotherapeutics, Ltd
Unspecified Adult Solid Tumor, Protocol Specific
SB939 in Treating Patients With Locally Advanced or Metastatic Solid Tumors
RATIONALE: SB939 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of SB939 in treating patients with locally…
- Trial name
- NCT00504296
- Testing
- HDAC inhibitor SB939, immunoenzyme technique, immunohistochemistry staining method
- Where
- 2 sites in Canada
- Volunteers
- 39 people
- Sponsor
- NCIC Clinical Trials Group
Non-Small Cell Lung Cancer With EGFR Mutation, Locally Advanced Solid Tumor
Advanced Lung Tumor Treated by Osimertinib Plus Anlotinib
This is a prospective, single arm, phase Ib/IIa study. Up to 25 patients will be enrolled into the study (Part A: 2-18; Part B: 7-19).
- Conditions
- Non-Small Cell Lung Cancer With EGFR Mutation, Locally Advanced Solid Tumor, Metastatic Cancer, Adenocarcinoma of Lung
- Trial name
- AUTOMAN (NCT04770688)
- Testing
- Osimertinib, Anlotinib
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Shanghai Chest Hospital
Cancer, Neoplasm Metastasis
Open Label Phase 1 Dose Finding Study of TRC105 in Patients With Solid Cancer
This study is being performed to evaluate the safety and tolerability of the TRC105 monoclonal antibody.
- Trial name
- NCT00582985
- Testing
- TRC105 chimeric anti-CD105 antibody
- Where
- 4 sites in United States
- Volunteers
- 51 people
- Sponsor
- Tracon Pharmaceuticals Inc.
Advanced Solid Tumor
L-TIL in Patients With Malignancy Resistance to Anti-PD-1 Therapy
Safety and effectiveness of liquid tumor infiltrating lymphocytes in patients with advanced malignant tumors who have failed to anti-PD-1 therapy
- Trial name
- NCT04268108
- Testing
- liquid tumor infiltrating lymphocytes
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Henan Cancer Hospital
Adult Solid Neoplasm, Recurrent Non-Small Cell Lung Carcinoma
Buparlisib, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors
This phase I trial studies the side effects and the best doses of buparlisib, gemcitabine hydrochloride, and cisplatin in treating patients with solid tumors that have spread to other places in the body.
- Conditions
- Adult Solid Neoplasm, Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer
- Trial name
- NCT01971489
- Testing
- Buparlisib, Cisplatin, Gemcitabine Hydrochloride
- Where
- United States
- Sponsor
- Roswell Park Cancer Institute
Neoplasms
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
This study aims to evaluate the safety and tolerability of RO7673396 in participants with advanced solid tumors harboring RAS mutation(s). This study consists of two stages: Stage 1 (Dose Escalation) and Stage 2 (Dose Expansion).
- Trial name
- NCT06884618
- Testing
- RO7673396
- Where
- 25 sites in United States, Australia and 9 more
- Volunteers
- 405 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.